Clinical

Dataset Information

0

Identification of the molecular basis of anti-cancer effect of Huaier.


ABSTRACT: Intervention type:DRUG. Intervention1:Huaier, Dose form:GRANULES, Route of administration:ORAL, intended dose regimen:20 to 60/day by either bulk or split for 3 months to extended term if necessary. Control intervention1:None. Primary outcome(s): For mRNA libraries, focus on mRNA studies. Data analysis includes sequencing data processing and basic sequencing data quality control, prediction of new transcripts, differential expression analysis of genes. Gene Ontology (GO) and the KEGG pathway database are used for annotation and enrichment analysis of up-regulated genes and down-regulated genes. For small RNA libraries, data analysis includes sequencing data process and sequencing data process QC, small RNA distribution across the genome, rRNA, tRNA, alignment with snRNA and snoRNA, construction of known miRNA expression pattern, prediction New miRNA and Study of their secondary structure Based on the expression pattern of miRNA, we perform not only GO / KEGG annotation and enrichment, but also different expression analysis.. Timepoint:RNA sequencing of 240 blood samples of 80 cases and its analysis, scheduled from June 30, 2022..

DISEASE(S): Cancers Such As Hepatocellular Carcinoma, Breast Cancer, Colorectal Cancer And Related Gastrointestinal Cancers, Urologic Cancers Including Prostate Cancer, Pancreas Cancer, And Lung Cancer), On Which A Significant Therapeutic Efficacy Of Huaier Has Been Reported. Special Remarks Is Emphasized On The Cancer Cases Designated To Be Related To Cancer Stem Cells

PROVIDER: 2612481 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 98681 | ecrin-mdr-crc
2024-09-02 | BIOMD0000000530 | BioModels
2023-05-10 | PXD031771 | Pride
2024-01-26 | PXD044936 | Pride
2019-08-12 | PXD013720 | Pride
2017-04-19 | PXD004748 | Pride
| phs001344 | dbGaP
2020-07-18 | PXD020425 |
2022-02-21 | GSE178629 | GEO
2021-01-19 | GSE149315 | GEO